The Novartis radioligand therapy Pluvicto® has become the first TGA registered RLT in Australia for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

Peter Mac's Professor Michael Hofman joined radio station 2GB to talk about this ground-breaking new treatment.